<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Mol Vis</journal-id><journal-id journal-id-type="publisher-id">MV</journal-id><journal-title>Molecular Vision</journal-title><issn pub-type="epub">1090-0535</issn><publisher><publisher-name>Molecular Vision</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">297</article-id><article-id pub-id-type="publisher-id">2008MOLVIS0294</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Small ubiquitin-like modifier 4 (<italic>SUMO4</italic>) polymorphisms and Vogt-Koyanagi-Harada (VKH) syndrome in the Chinese Han population</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hou</surname><given-names>Shengping</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Yang</surname><given-names>Peizeng</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Du</surname><given-names>Liping</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zhou</surname><given-names>Hongyan</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lin</surname><given-names>Xiaomin</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Xiaoli</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kijlstra</surname><given-names>Aize</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><aff id="aff1"><label>1</label>The First Affiliated Hospital, Chongqing Medical University, Chongqing Key Laboratory of Ophthalmology, Chongqing, P.R. China</aff><aff id="aff2"><label>2</label>Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, P.R. China</aff><aff id="aff3"><label>3</label>Eye Research Institute Maastricht, Department of Ophthalmology, University Hospital Maastricht, Maastricht, the Netherlands</aff></contrib-group><author-notes><corresp id="cor1">Correspondence to: Professor Peizeng Yang, MD, Ph.D., The First Affiliated Hospital, Chongqing Medical University, Chongqing Key Laboratory of Ophthalmology, Chongqing, P.R. China, 400016; Phone: +8623 89012851; FAX: +8623 89012851; email: <email xlink:href="peizengy@126.com">peizengy@126.com</email></corresp></author-notes><pub-date pub-type="collection"><year>2008</year></pub-date><pub-date pub-type="epub"><day>31</day><month>12</month><year>2008</year></pub-date><volume>14</volume><fpage>2597</fpage><lpage>2603</lpage><history><date date-type="received"><day>03</day><month>9</month><year>2008</year></date><date date-type="accepted"><day>29</day><month>12</month><year>2008</year></date></history><permissions><copyright-year>2008</copyright-year><copyright-holder>Molecular Vision</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract><sec><title>Purpose</title><p>To examine whether small ubiquitin-like modifier 4 (<italic>SUMO4</italic>) polymorphisms were associated with Vogt-Koyanagi-Harada (VKH) syndrome in the Chinese Han population.</p></sec><sec sec-type="methods"><title>Methods</title><p>Genotyping for <italic>SUMO4</italic> polymorphisms at G-847A, A-504G, A+163G, and C+438T loci was performed on 231 VKH patients and 302 controls using polymerase chain reaction restriction fragment length polymorphism.</p></sec><sec><title>Results</title><p>A decreased frequency of <italic>SUMO4</italic> +438 TT genotype was found in VKH patients compared with healthy controls (p=0.009). However, the significance was lost after Bonferroni correction. Human leukocyte antigens (<italic>HLA)-DR4</italic> and <italic>HLA-DRw53</italic> were significantly associated with susceptibility to VKH syndrome (p=3.21&#x000d7;10<sup>&#x02212;16</sup> and 7.08&#x000d7;10<sup>&#x02212;5</sup>, respectively). Stratification analysis based on <italic>HLA-DR4</italic> and <italic>HLA-DRw53</italic> did not show any associations between <italic>SUMO4</italic> polymorphisms and VKH syndrome, although there was a big difference in the percentage of certain allele and genotype frequencies between <italic>HLA-DRw53</italic> negative patients and controls. There was no significance in clinical findings and gender stratification analysis.</p></sec><sec><title>Conclusions</title><p><italic>HLA-DR4</italic> and <italic>HLA-DRw53</italic> are strongly associated with the susceptibility to VKH syndrome in the Chinese Han population. However, none of the currently known single nucleotide polymorphisms (SNPs) of <italic>SUMO4</italic> are associated with this syndrome.</p></sec></abstract><custom-meta-wrap><custom-meta><meta-name>GalleyStatus</meta-name><meta-value>Export to XML</meta-value></custom-meta></custom-meta-wrap></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Vogt-Koyanagi-Harada (VKH)syndrome is one of the most common uveitis entities in China [<xref ref-type="bibr" rid="r1">1</xref>]. It is characterized by a granulomatous panuveitis frequently in association with extraocular findings such as pleocytosis in the cerebrospinal fluid (CSF), dysacusis, alopecia, poliosis, and vitiligo [<xref ref-type="bibr" rid="r2">2</xref>-<xref ref-type="bibr" rid="r4">4</xref>]. Although the exact pathogenesis of VKH syndrome remains unclear, numerous studies have shown that immunogenetic factors are involved in the development of this syndrome. T cells autoreactive against tyrosinase family proteins are possibly involved in VKH syndrome. Meanwhile, genetic factors also play an important role in VKH syndrome as evidenced by the increased rates of this syndrome in pigmented groups [<xref ref-type="bibr" rid="r2">2</xref>], familial aggregation [<xref ref-type="bibr" rid="r5">5</xref>-<xref ref-type="bibr" rid="r7">7</xref>], and strong association with human leukocyte antigens (<italic>HLA</italic>)-<italic>DR4</italic> and <italic>HLA-DRw53</italic> in various ethnic groups including the Chinese and Japanese [<xref ref-type="bibr" rid="r8">8</xref>-<xref ref-type="bibr" rid="r10">10</xref>]. However, little is known about the genes that present susceptibility to the VKH syndrome except <italic>HLA</italic> [<xref ref-type="bibr" rid="r11">11</xref>-<xref ref-type="bibr" rid="r13">13</xref>].</p><p>Recently, studies have demonstrated that multiple autoimmune diseases may share common susceptibility genes by whole genome association and family based association studies [<xref ref-type="bibr" rid="r14">14</xref>-<xref ref-type="bibr" rid="r17">17</xref>]. Therefore, susceptibility genes associated with other autoimmune diseases may be candidates in the study of gene susceptibility to VKH syndrome, an autoimmune uveitis commonly seen in China. Small ubiquitin-like modifier 4 (<italic>SUMO4</italic>) is located on chromosome 6p25. Recently, certain <italic>SUMO4</italic> polymorphisms have been shown to be clearly associated with type 1 diabetes in multiple Asian populations [<xref ref-type="bibr" rid="r18">18</xref>,<xref ref-type="bibr" rid="r19">19</xref>] as well as with other autoimmune diseases [<xref ref-type="bibr" rid="r19">19</xref>-<xref ref-type="bibr" rid="r22">22</xref>], despite controversial observations in Caucasians [<xref ref-type="bibr" rid="r18">18</xref>,<xref ref-type="bibr" rid="r23">23</xref>-<xref ref-type="bibr" rid="r25">25</xref>]. <italic>SUMO4</italic> polymorphisms could also be involved in the pathogenesis of VKH syndrome, and this hypothesis was therefore the subject of the study presented here.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Subjects</title><p>Blood samples were collected from 231 Chinese Han VKH patients (128 males and 103 females) and 302 age- and sex-matched, unrelated Chinese Han healthy controls (164 males and 138 females), which were recruited from the Uveitis Study Center of the Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, P.R. China and The First Affiliated Hospital, Chongqing Medical University, Chongqing, P.R. China. The institutional ethics committee of Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, P.R. China approved this study, and informed consent was obtained from all tested subjects.</p></sec><sec><title>DNA extraction</title><p>Genomic DNA samples were extracted and isolated from ethylene diamine tetraacetic acid (EDTA) anti-coagulated peripheral blood mononuclear cells (PBMCs) of VKH patients and healthy controls by a conventional salting out method. These DNA samples were diluted in PCR grade water and stored at &#x02212;70 &#x000b0;C until used.</p></sec><sec><title>Genotyping</title><p>Polymerase chain reaction (PCR) was performed using primers at G-847A locate (Forward, 5&#x02032;-TCC CAA CCA ATA ATA GCA AGT CT-3&#x02032;; Reverse, 5&#x02032;-ATG CCT GGA TCA AAA CAC ACA-3&#x02032;), A-504G locate (Forward, 5&#x02032;- TGT GTG TTT TGA TCC AGG CAT TA-3&#x02032;; Reverse, 5&#x02032;-TGT TTT GCT CCT CTT TTC CTC TT-3&#x02032;), A+163G locate (Forward, 5&#x02032;-ATT GTG AAC CAC GGG GAT TGT TA-3&#x02032;; Reverse, 5&#x02032;-CAGCGTTCTGGAGTAAAGAAG-3&#x02032;), and C+438T locate (Forward, 5&#x02032;-ATA CCA GTT ACT TCA TGT ATA ATA GA-3&#x02032;; Reverse, 5&#x02032;-AGA TTA CTG CAT TCT CAA TTA G &#x02212;3&#x02032;). PCR products at G-847A (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=237026">rs237026</ext-link>), A-504G (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=600739">rs600739</ext-link>), A+163G (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=237025">rs237025</ext-link>), and C+438T (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=237024">rs237024</ext-link>) loci were incubated with SspI at 37&#x000a0;&#x000b0;C, Alw21I at 37&#x000a0;&#x000b0;C, MseI at 65&#x000a0;&#x000b0;C, and MnlI at 37&#x000a0;&#x000b0;C (MBI Fermentas, Vilnius, Lithuania) for at least 4 h, respectively. PCR fragments were separated on 3% agarose gels. Twenty percent of the PCR samples were directly sequenced to confirm the polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) results (Invitrogen Biotechnology Co., Guangzhou, China). <italic>HLA-DR4</italic> genotyping was performed using the PCR sequence specific primers (SSP) method as previously described [<xref ref-type="bibr" rid="r26">26</xref>]. <italic>HLA-DRw53</italic> genotyping was performed as previously described [<xref ref-type="bibr" rid="r27">27</xref>].</p></sec><sec><title>Statistical analysis</title><p>The &#x003c7;<sup>2</sup> test was applied to analyze the Hardy&#x02013;Weinberg equilibrium (HWE). The &#x003c7;<sup>2</sup> test or Fisher&#x02019;s exact test was performed to compare the allelic, genotypic, and haplotypic distribution between VKH patients and healthy controls using version 12.0 of SPSS for Windows (SPSS Inc., Chicago, IL). Analysis of linkage disequilibrium (LD) of each SNP and haplotype was performed using the <ext-link ext-link-type="uri" xlink:href="http://www.broad.mit.edu/haploview/haploview-downloads">Haploview</ext-link> v3.32 program [<xref ref-type="bibr" rid="r28">28</xref>,<xref ref-type="bibr" rid="r29">29</xref>]. The p values were corrected using the Bonferroni correction to account for multiple testing. Sample sizes were estimated by Quanto 1.2 software (Department of Preventive Medicine, University of Southern California, Los Angles, CA).</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Descriptive data of the tested patients and controls</title><p>Detailed clinical findings of the enrolled VKH patients are shown in <xref ref-type="table" rid="t1">Table1</xref>. The average age of the VKH patients was 33.6&#x000b1;12.4 years and that of healthy controls was 35.4&#x000b1;12.0 years. No statistical difference was observed between VKH patients and controls in the distribution of age and gender (p&#x0003e;0.05).</p><table-wrap id="t1" position="float"><label>Table 1</label><caption><title><italic>HLA-DR4</italic> and <italic>HLA-DRw53 </italic>distribution and clinical findings of patients with VKH syndrome.</title></caption><table frame="hsides" rules="groups"><col width="93" span="1"/><col width="79" span="1"/><col width="79" span="1"/><col width="86" span="1"/><col width="86" span="1"/><thead><tr><th rowspan="2" valign="top" align="center" scope="col" colspan="1"><bold>Characteristics</bold>&#x02028;&#x000a0;</th><th colspan="4" valign="top" align="center" scope="colgroup" rowspan="1"><bold>VKH Patients</bold><hr/></th></tr><tr><th valign="top" colspan="1" align="center" scope="colgroup" rowspan="1"><bold><italic>HLA-DR4 +</italic></bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold><italic>HLA-DR4 -</italic></bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold><italic>HLA-DRw53 +</italic></bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold><italic>HLA-DRw53 -</italic></bold></th></tr></thead><tbody><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">Number of patients (%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">179 (77.5%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">52 (22.5%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">203 (87.9%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">28 (12.1%)<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">Male<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">103 (80.5%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">25 (19.5%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">116 (90.6%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">12 (9.4%)<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">Female<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">76 (73.8%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">27 (26.2%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">87 (84.5%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">16 (15.5%)<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">Neck stiffness<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">74 (72.5%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">28 (27.5%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">89 (87.3%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">13 (12.7%)<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">Alopecia<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">26 (72.2%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">10 (27.8%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">30 (83.3%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">6 (16.7%)<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">Poliosis<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">65 (73.9%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">23 (26.1%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">78 (88.6%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">10 (11.4%)<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">Vitiligo<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">41 (74.5%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">14 (25.5%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">48 (87.3%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">7 (12.7%)<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">Dysacusia<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">57 (69.5%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">25 (30.5%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">70 (85.4%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">12 (14.6%)<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">Tinnitus<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">61 (84.7%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">11 (15.3%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">67 (93.1%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">5 (6.9%)<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">Scalp hypersensitivity</td><td valign="top" align="center" rowspan="1" colspan="1">32 (74.4%)</td><td valign="top" align="center" rowspan="1" colspan="1">11 (25.6%)</td><td valign="top" align="center" rowspan="1" colspan="1">38 (88.4%)</td><td valign="top" align="center" rowspan="1" colspan="1">5 (11.6%)</td></tr></tbody></table><table-wrap-foot><p>The age at onset (years&#x000b1;SD) for all VKH patients was 33.6&#x000b1;12.4 years.</p></table-wrap-foot></table-wrap></sec><sec><title>Single nucleotide polymorphism and haplotype analyses between polymorphisms of <italic>SUMO4</italic> and Vogt-Koyanagi-Harada syndrome</title><p>The distribution of genotype for each SNP including G-847A, A-504G, A+163G, and C+438T did not deviate from the HWE in VKH patients and healthy controls (p&#x0003e;0.05). A decreased frequency of <italic>SUMO4</italic> +438 TT genotype was observed in VKH patients compared with healthy controls (p=0.009, &#x003c7;<sup>2</sup>=9.36). However, it did not remain significant after Bonferroni correction (<xref ref-type="table" rid="t2">Table 2</xref>).</p><table-wrap id="t2" position="float"><label>Table 2</label><caption><title>The comparison of allele and genotype frequencies for the four polymorphisms of <italic>SUMO4 </italic>gene in VKH patients and controls.</title></caption><table frame="hsides" rules="groups"><col width="78" span="1"/><col width="62" span="1"/><col width="62" span="1"/><col width="62" span="1"/><col width="62" span="1"/><col width="62" span="1"/><col width="62" span="1"/><col width="59" span="1"/><thead><tr><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>SNPs</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>Genotype allele</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>VKH n=231 (%)</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>Controls n=302 (%)</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>&#x003c7;<sup>2</sup></bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>p value</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>pc<sup>a</sup> value</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>OR</bold>&#x02028;<bold>(95% CI)</bold></th></tr></thead><tbody><tr><td rowspan="5" valign="top" align="center" scope="row" colspan="1">&#x02212;847 G&#x02192;A<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">GG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">16 (7.1)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">30 (10.1)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">3.15<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.207<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NS<sup>b</sup><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">AG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">104 (46.0)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">116 (39.2)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">AA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">106 (46.9)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">150 (50.7)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">G<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">117 (30.1)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">176 (29.7)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2.38<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.120<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NS<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.0 (0.8&#x02013;1.3)<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">A<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">343 (69.9)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">416 (70.3)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td rowspan="5" valign="top" align="center" scope="row" colspan="1">&#x02212;504 A&#x02192;G<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">AA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">54 (24.0)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">66 (22.2)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.25<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.885<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NS<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">AG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">107 (47.6)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">146 (49.2)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">GG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">64 (28.4)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">85 (28.6)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">A<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">215 (47.8)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">278 (46.8)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.10<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.754<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NS<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.0 (0.8&#x02013;1.3)<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">G<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">235 (52.2)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">316 (53.2)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td rowspan="5" valign="top" align="center" scope="row" colspan="1">+163 A&#x02192;G<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">AA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">107 (46.5)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">145 (48.0)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.05<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.591<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NS<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">AG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">107 (46.5)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">130 (43.0)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">GG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">16 (7.0)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">27 (8.9)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">A<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">319 (69.7)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">420 (69.5)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.002<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.968<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NS<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.0 (0.8&#x02013;1.3)<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">G<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">139 (30.3)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">184 (30.5)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td rowspan="5" valign="top" align="center" scope="row" colspan="1">+438 C&#x02192;T</td><td valign="top" align="center" rowspan="1" colspan="1">CC<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">107 (46.7)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">135 (44.7)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">9.36<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.009<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NS<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">CT<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">107 (46.7)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">122 (40.4)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">TT<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">15 (6.6)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">45 (14.9)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">C<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">320 (70.2)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">392 (64.9)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">3.18<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.075<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NS<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.3 (1.0&#x02013;1.6)<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">T</td><td valign="top" align="center" rowspan="1" colspan="1">136 (29.8)</td><td valign="top" align="center" rowspan="1" colspan="1">212 (35.1)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><p><sup>a</sup> Bonferroni corrected p value; <sup>b</sup>Not significant.</p></table-wrap-foot></table-wrap><p>Haplotype analysis using the <ext-link ext-link-type="uri" xlink:href="http://www.broad.mit.edu/haploview/haploview-downloads">Haploview</ext-link> 3.32 software showed that the four SNPs were in strong linkage (D&#x02019;=84&#x02013;91). A decreased frequency of <italic>SUMO4</italic> haplotype (&#x02212;847A, &#x02212;504G, +163A, and +438T) was observed in VKH patients compared with healthy controls (p=0.008, &#x003c7;<sup>2</sup>=7.07). However, the significance was lost after Bonferroni correction (<xref ref-type="table" rid="t3">Table 3</xref>).</p><table-wrap id="t3" position="float"><label>Table 3</label><caption><title>The comparison of frequencies of <italic>SUMO4</italic> haplotypes in VKH Patients and controls.</title></caption><table frame="hsides" rules="groups"><col width="67" span="1"/><col width="59" span="1"/><col width="62" span="1"/><col width="55" span="1"/><col width="57" span="1"/><col width="57" span="1"/><col width="65" span="1"/><thead><tr><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>Haplotype</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>VKH n=231 (%)</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>Control n=302 (%)</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>&#x003c7;<sup>2</sup></bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>p value</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>pc<sup>a</sup> value</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>OR</bold>&#x02028;<bold>(95% CI)</bold></th></tr></thead><tbody><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">AGAC<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">228.2 (49.8)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">274.6 (45.5)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.99<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.158<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NS<sup>b</sup><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.2 (0.9&#x02013;1.5)<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">GAGT<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">126.4 (27.6)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">156.3 (25.9)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.40<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.529<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NS<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.1 (0.8&#x02013;1.4)<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">AAAC<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">79.1 (17.3)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">101.5 (16.8)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.04<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.839<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NS<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1.0 (0.8&#x02013;1.5)<hr/></td></tr><tr><td valign="top" align="center" scope="row" rowspan="1" colspan="1">AGAT</td><td valign="top" align="center" rowspan="1" colspan="1">4.8 (1.0)</td><td valign="top" align="center" rowspan="1" colspan="1">21.9 (3.6)</td><td valign="top" align="center" rowspan="1" colspan="1">7.07</td><td valign="top" align="center" rowspan="1" colspan="1">0.008</td><td valign="top" align="center" rowspan="1" colspan="1">NS</td><td valign="top" align="center" rowspan="1" colspan="1">0.2 (0.06&#x02013;0.4)</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup> Bonferroni corrected p value; <sup>b</sup>Not significant.</p></table-wrap-foot></table-wrap></sec><sec><title>Stratification analysis of <italic>SUMO4</italic> polymorphisms with the status of <italic>HLA-DR4</italic>, <italic>HLA-DRw53</italic>, the clinical findings, and gender</title><p>Our study showed that the frequency of <italic>HLA-DR4</italic> was significantly increased in 231 VKH patients as compared with that in 302 healthy controls (77.5% versus 19.5%, p=3.21&#x000d7;10<sup>&#x02212;16</sup>, &#x003c7;<sup>2</sup>=66.67, OR=13.74, 95% CI=6.99&#x02013;26.98). <italic>HLA-DRw53</italic> was also shown to be significantly associated with susceptibility to VKH syndrome in the Chinese Han population (87.9% versus 63.9%, p=7.08&#x000d7;10<sup>&#x02212;5</sup>, &#x003c7;<sup>2</sup>=15.79, OR=4.13, 95% CI=1.99&#x02013;8.55). To test whether there was an influence of <italic>HLA-DR4</italic> and <italic>DRw53</italic> on the <italic>SUMO4</italic> association, stratification analysis was performed according to these parameters. The allele and genotype frequencies of the four SNPs of <italic>SUMO4</italic> were not different between <italic>HLA-DR4</italic> positive patients and <italic>HLA-DR4</italic> positive controls and between <italic>HLA-DR4</italic> negative patients and <italic>HLA-DR4</italic> negative controls (<xref ref-type="table" rid="t4">Table 4</xref>). Similar results were also observed in <italic>HLA-DRw53</italic> stratification analysis (<xref ref-type="table" rid="t5">Table 5</xref>). However, a big difference was observed in <italic>HLA-DRw53</italic> negative patients compared with <italic>HLA-DRw53</italic> negative controls (G-847A: AA genotype, <italic>HLA-DRw53</italic>- patients versus <italic>HLA-DRw53</italic>- controls: 40.7% versus 59.4%, AG genotype, <italic>HLA-DRw53</italic>- patients versus <italic>HLA-DRw53</italic>- controls: 48.1% versus 31.1%; A-504G: AA genotype, <italic>HLA-DRw53</italic>- patients versus <italic>HLA-DRw53</italic>- controls: 40.8% versus 21.5%, A allele, <italic>HLA-DRw53</italic>- patients versus <italic>HLA-DRw53</italic>- controls: 59.3% versus 43.9%; A+163G: AA genotype, <italic>HLA-DRw53</italic>- patients versus <italic>HLA-DRw53</italic>- controls: 39.3% versus 56.9%, AG genotype, <italic>HLA-DRw53</italic>- patients versus <italic>HLA-DRw53</italic>- controls: 50.0% versus 33.0%; <xref ref-type="table" rid="t5">Table 5</xref>).</p><table-wrap id="t4" position="float"><label>Table 4</label><caption><title>Stratification analysis for <italic>HLA-DR4</italic> and <italic>SUMO4</italic> polymorphisms and the comparison of frequencies of <italic>SUMO4 </italic>allele and genotype in<italic> HLA-DR4</italic>+ patients versus <italic>HLA-DR4</italic>+ controls and <italic>HLA-DR4</italic>- patients versus <italic>HLA-DR4</italic>- controls.</title></caption><table frame="hsides" rules="groups"><col width="40" span="1"/><col width="60" span="1"/><col width="69" span="1"/><col width="69" span="1"/><col width="50" span="1"/><col width="57" span="1"/><col width="66" span="1"/><col width="66" span="1"/><col width="38" span="1"/><col width="38" span="1"/><thead><tr><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>SNPs</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>Genotype allele</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold><italic>HLA-DR4</italic>+ Patients n=179 (%)</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold><italic>HLA-DR4</italic>+ Controls n=59 (%)</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>p value</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>pc<sup>a</sup> value</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold><italic>HLA-DR4</italic>- Patients n=52 (%)</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold><italic>HLA-DR4</italic>- Controls n=243 (%)</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>p value</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>pc<sup>a</sup> value</bold></th></tr></thead><tbody><tr><td rowspan="5" valign="top" align="center" scope="row" colspan="1">&#x02212;847 G&#x02192;A<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">GG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">12 (6.8)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">10 (17.2)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.041<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NS<sup>b</sup><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">4 (8.0)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">20(8.4)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.757<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NS<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">AG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">81 (46.0)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">20 (34.5)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">23 (46.0)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">96 (40.3)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">AA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">83 (47.2)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">28 (48.3)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">23 (46.0)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">122 (51.3)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">G<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">105 (29.8)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">40 (34.5)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.347<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NS<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">31 (31.0)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">136 (28.6)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.627<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NS<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">A<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">247 (70.2)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">76 (65.5)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">69 (69.0)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">340 (71.4)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td rowspan="5" valign="top" align="center" scope="row" colspan="1">&#x02212;504 A&#x02192;G<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">AA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">40 (22.9)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">11 (19.0)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.656<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NS<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">14 (28.0)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">55 (23.0)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.696<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NS<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">AG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">85 (48.6)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">27 (46.6)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">22 (44.0)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">119 (49.8)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">GG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">50 (28.6)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">20 (34.5)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">14 (28.0)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">65 (27.2)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">A<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">165 (47.1)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">49 (42.2)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.359<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NS<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">50 (50.0)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">249 (52.1)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.703<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NS<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">G<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">185 (52.9)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">67 (57.8)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">50 (50.0)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">229 (47.9)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td rowspan="5" valign="top" align="center" scope="row" colspan="1">+163 A&#x02192;G<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">AA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">84 (46.9)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">29 (49.2)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.820<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NS<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">23 (45.1)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">116 (47.7)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.872<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NS<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">AG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">83 (46.4)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">25 (42.4)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">24 (47.1)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">105 (43.2)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">GG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">12 (6.7)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">5 (8.5)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">4 (7.8)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">22 (9.1)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">A<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">251 (70.1)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">83 (70.3)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.963<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NS<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">70 (68.6)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">337 (69.3)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.887<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NS<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">G<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">107 (29.9)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">35 (29.7)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">32 (31.4)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">149 (30.7)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td rowspan="5" valign="top" align="center" scope="row" colspan="1">+438 C&#x02192;T</td><td valign="top" align="center" rowspan="1" colspan="1">CC<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">82 (46.3)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">29 (49.2)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.089<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NS<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">25 (48.1)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">106 (43.6)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.562<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NS<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">CT<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">85 (48.0)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">22 (37.3)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">22 (42.3)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">100 (41.2)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">TT<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">10 (5.6)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">8 (13.6)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">5 (9.6)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">37 (15.2)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">C<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">249 (70.3)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">80 (67.8)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.603<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NS<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">72 (69.2)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">312 (64.2)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.328<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NS<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">T</td><td valign="top" align="center" rowspan="1" colspan="1">105 (29.7)</td><td valign="top" align="center" rowspan="1" colspan="1">38 (32.2)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;</td><td valign="top" align="center" rowspan="1" colspan="1">32 (30.8)</td><td valign="top" align="center" rowspan="1" colspan="1">174 (35.8)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><p><sup>a</sup> Bonferroni corrected p value; <sup>b</sup>Not significant.</p></table-wrap-foot></table-wrap><table-wrap id="t5" position="float"><label>Table 5</label><caption><title>Stratification analysis for <italic>HLA-DRw53</italic> and <italic>SUMO4</italic> polymorphisms and the comparison of frequencies of <italic>SUMO4 </italic>allele and genotype in<italic> HLA-DRw53</italic>+ patients versus <italic>HLA-DRw53</italic>+ controls and <italic>HLA-DRw53</italic>- patients versus <italic>HLA-DRw53</italic>- controls.</title></caption><table frame="hsides" rules="groups"><col width="40" span="1"/><col width="42" span="1"/><col width="83" span="1"/><col width="83" span="1"/><col width="38" span="1"/><col width="38" span="1"/><col width="80" span="1"/><col width="80" span="1"/><col width="38" span="1"/><col width="38" span="1"/><thead><tr><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>SNPs</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>Genotype allele</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold><italic>HLA-DRw53</italic>+ Patients n=203 (%)</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold><italic>HLA-DRw53</italic>+ Controls n=193 (%)</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>p value</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>pc<sup>a</sup> value</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold><italic>HLA-DRw53</italic>- Patients n=28 (%)</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold><italic>HLA-DRw53</italic>- Controls n=109 (%)</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>p value</bold></th><th valign="top" align="center" scope="col" rowspan="1" colspan="1"><bold>pc<sup>a</sup> value</bold></th></tr></thead><tbody><tr><td rowspan="5" valign="top" align="center" scope="row" colspan="1">&#x02212;847 G&#x02192;A<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">GG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">13 (6.5)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">20 (10.5)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.368<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NS<sup>b</sup><hr/></td><td valign="top" align="center" rowspan="1" colspan="1">3 (11.1)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">10 (9.4)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.200<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NS<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">AG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">91 (45.7)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">83 (43.7)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">13 (48.1)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">33 (31.1)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">AA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">95 (47.7)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">87 (45.8)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">11 (40.7)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">63 (59.4)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">G<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">117 (29.4)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">123 (32.4)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.370<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NS<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">19 (35.2)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">53 (25.0)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.133<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NS<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">A<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">281 (70.6)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">257 (67.6)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">35 (64.8)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">159 (75.0)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td rowspan="5" valign="top" align="center" scope="row" colspan="1">&#x02212;504 A&#x02192;G<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">AA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">43 (21.7)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">43 (22.6)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.742<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NS<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">11 (40.8)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">23 (21.5)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.114<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NS<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">AG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">97 (49.0)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">98 (51.6)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">10 (37.0)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">48 (44.9)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">GG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">58 (29.3)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">49 (25.8)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">6 (22.2)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">36 (33.6)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">A<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">183 (46.2)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">184 (48.4)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.538<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NS<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">32 (59.3)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">94 (43.9)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.044<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NS<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">G<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">213 (53.8)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">196 (51.6)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">22 (40.7)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">120 (56.1)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td rowspan="5" valign="top" align="center" scope="row" colspan="1">+163 A&#x02192;G<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">AA<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">96 (47.5)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">83 (43.0)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.590<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NS<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">11 (39.3)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">62 (56.9)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.216<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NS<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">AG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">93 (46.0)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">94 (48.7)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">14 (50.0)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">36 (33.0)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">GG<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">13 (6.4)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">16 (8.3)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">3 (10.7)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">11 (10.1)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">A<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">285 (70.5)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">260 (67.4)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.333<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NS<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">36 (64.3)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">160 (73.4)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.178<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NS<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">G<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">119 (29.5)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">126 (32.6)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">20 (35.7)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">58 (26.6)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td rowspan="5" valign="top" align="center" scope="row" colspan="1">+438 C&#x02192;T</td><td valign="top" align="center" rowspan="1" colspan="1">CC<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">95 (47.3)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">82 (42.5)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.035<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NS<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">12 (42.9)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">53 (48.6)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.613<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NS<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">CT<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">95 (47.3)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">86 (44.6)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">12 (42.9)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">36 (33.0)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">TT<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">11 (5.5)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">25 (13.0)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">4 (14.3)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">20 (18.3)<hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td><td valign="top" align="left" rowspan="1" colspan="1"><hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">C<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">285 (70.9)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">250 (64.8)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.065<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NS<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">36 (64.3)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">142 (65.1)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.905<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">NS<hr/></td></tr><tr><td valign="top" colspan="1" align="center" scope="row" rowspan="1">T</td><td valign="top" align="center" rowspan="1" colspan="1">117 (29.1)</td><td valign="top" align="center" rowspan="1" colspan="1">136 (35.2)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;</td><td valign="top" align="center" rowspan="1" colspan="1">&#x000a0;</td><td valign="top" align="center" rowspan="1" colspan="1">20 (35.7)</td><td valign="top" align="center" rowspan="1" colspan="1">76 (34.9)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Bonferroni corrected p value; <sup>b</sup>Not significant.</p></table-wrap-foot></table-wrap><p>Stratification analysis was also performed according to clinical findings including neck stiffness, tinnitus, alopecia, poliosis, dysacusis, scalp hypersensitivity, and vitiligo. No association was found between the four SNPs and any extraocular findings. The analysis of gender stratification also showed no association of <italic>SUMO4</italic> polymorphisms with VKH syndrome.</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>In this study, we examined the association of <italic>SUMO4</italic> polymorphisms with VKH syndrome in the Chinese Han population. Our results failed to find an association between <italic>SUMO4</italic> polymorphisms and VKH syndrome even after stratification for <italic>HLA-DR4</italic>, <italic>HLA-DRw53</italic>, clinical features, and gender.</p><p><italic>SUMO4</italic> has been shown to be involved in the regulation of <italic>NF-&#x0043a;B</italic>, an important transcription factor in autoimmune diseases. It has been reported that the <italic>SUMO4</italic> A+163G (M55V) polymorphism is an essential polymorphism involved in regulating its own sumoylation, and it has been shown to be associated with certain autoimmune diseases such as type 1 diabetes, autoimmune thyroid disease, and rheumatoid arthritis without amyloidosis [<xref ref-type="bibr" rid="r19">19</xref>]. These results suggest that this polymorphism could be a susceptibility gene shared by certain autoimmune diseases, although conflicting data have been reported in Sj&#x000f6;gren&#x02019;s syndrome [<xref ref-type="bibr" rid="r19">19</xref>]. The identification of a general susceptibility gene for several autoimmune diseases could make an important contribution to the understanding of the pathogenesis and modulation of these diseases. The question was therefore raised whether the <italic>SUMO4</italic> A+163G polymorphism was also associated with VKH syndrome. This study was designed to clarify this issue. We strictly chose the patients who were definitely diagnosed with VKH syndrome according to the revised criteria [<xref ref-type="bibr" rid="r30">30</xref>] to exclude the influence of misdiagnosis. As ethnic confounding could also influence the association results, only VKH patients with Chinese Han nationality as well as age- and sex-matched controls with the same nationality were enrolled in this study. The frequency of the +163G allele in the control population presented in our study is similar with that in the Chinese population reported by Li et al. [<xref ref-type="bibr" rid="r31">31</xref>] and in the Japanese population reported by Noso et al. [<xref ref-type="bibr" rid="r20">20</xref>]. Meanwhile, a power analysis of the study population showed that our sample size was large enough to detect a possible association. Unexpectedly, we failed to find an association of the <italic>SUMO4</italic> A+163G polymorphism with VKH syndrome. This suggests that this polymorphism may not be involved in the development of susceptibility to VKH syndrome.</p><p>Others SNPs including G-847A, A-504G, and C+438T polymorphisms have been identified by direct sequencing of the whole <italic>SUMO4</italic> gene in the Japanese population [<xref ref-type="bibr" rid="r20">20</xref>,<xref ref-type="bibr" rid="r32">32</xref>]. Our previous results showed an association of <italic>SUMO4</italic> C+438T polymorphism with Behcet&#x02019;s disease [<xref ref-type="bibr" rid="r22">22</xref>], another common uveitis entity observed in China. The present study also failed to show any association of the <italic>SUMO4</italic> G-847A, A-504G, and C+438T polymorphisms with VKH syndrome. This difference may result from the different features of these two uveitis entities. One of the striking features of Behcet&#x02019;s disease is its characteristic non-granulomatous inflammation while VKH syndrome is in fact a granulomatous inflammation [<xref ref-type="bibr" rid="r33">33</xref>].</p><p>Like <italic>HLA-DR4, HLA-DRw53</italic> have been demonstrated to be strongly associated with VKH syndrome. Therefore, genotyping of <italic>HLA-DR4</italic> and <italic>HLA-DRw53</italic> was performed. The association of <italic>HLA-DR4</italic> and <italic>HLA-DRw53</italic> with VKH syndrome was extremely strong in this study. The results were generally consistent with those previously reported in Chinese [<xref ref-type="bibr" rid="r4">4</xref>,<xref ref-type="bibr" rid="r8">8</xref>,<xref ref-type="bibr" rid="r34">34</xref>] and Spanish patients [<xref ref-type="bibr" rid="r35">35</xref>]. Furthermore, stratification analysis according to <italic>HLA-DR4</italic> and <italic>HLA-DRw53</italic> did not show any association of <italic>SUMO4</italic> with VKH syndrome in our study. This result is consistent with the previous studies that <italic>SUMO4</italic> M55V polymorphism was independent of the <italic>HLA</italic> class II haplotype [<xref ref-type="bibr" rid="r19">19</xref>,<xref ref-type="bibr" rid="r32">32</xref>], which is located on the same chromosome 6 as <italic>SUMO4</italic>.</p><p>It is worthy to point out that there was a big difference in the percentages of certain alleles and genotypes between <italic>HLA-DRw53</italic> negative patients and controls, although the difference did not reach statistical significance. As the sample size of <italic>HLA-DRw53</italic> negative is small (28 patients), it is necessary to further test the association of <italic>SUMO4</italic> polymorphisms with <italic>HLA-DRw53</italic> negative patients using larger samples.</p><p>In conclusion, we failed to detect an association of <italic>SUMO4</italic> polymorphisms with VKH syndrome in Chinese Han population. In agreement with earlier studies, we found a strong association of <italic>HLA-DR4</italic> and <italic>HLA-DRw53</italic> with susceptibility to VKH syndrome. A big but insignificant difference of allele and genotype frequency was noted in <italic>HLA-DRw53</italic> negative patients when compared with <italic>HLA-DRw53</italic> negative controls. Further studies are necessary to elucidate the association of <italic>SUMO4</italic> polymorphisms with VKH syndrome in a <italic>HLA-DRw53</italic> negative population using larger samples.</p></sec></body><back><ack><title>Acknowledgments</title><p>This work was supported by Project of International Cooperation in Science and Technology, Guangdong Province (2006A50107001), Key Project of Natural Science Foundation (30630064), National supporting project of P.R. China and Key Project of Health Bureau and Key Project of Science and Technology Committee of Chongqing. Thanks to all subjects enrolled in the present study.</p></ack><ref-list><title>References</title><ref id="r1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>L</given-names></name><name><surname>Ren</surname><given-names>Y</given-names></name><name><surname>Klooster</surname><given-names>J</given-names></name><name><surname>Kijlstra</surname><given-names>A</given-names></name></person-group><article-title>Clinical patterns and characteristics of uveitis in a tertiary center for uveitis in China.</article-title><source>Curr Eye Res</source><year>2005</year><volume>30</volume><fpage>943</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">16282128</pub-id></citation></ref><ref id="r2"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moorthy</surname><given-names>RS</given-names></name><name><surname>Inomata</surname><given-names>H</given-names></name><name><surname>Rao</surname><given-names>NA</given-names></name></person-group><article-title>Vogt-Koyanagi-Harada syndrome.</article-title><source>Surv Ophthalmol</source><year>1995</year><volume>39</volume><fpage>265</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">7725227</pub-id></citation></ref><ref id="r3"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Forster</surname><given-names>DJ</given-names></name><name><surname>Cano</surname><given-names>MR</given-names></name><name><surname>Green</surname><given-names>RL</given-names></name><name><surname>Rao</surname><given-names>NA</given-names></name></person-group><article-title>Echographic features of the Vogt-Koyanagi-Harada syndrome.</article-title><source>Arch Ophthalmol</source><year>1990</year><volume>108</volume><fpage>1421</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">2222275</pub-id></citation></ref><ref id="r4"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>P</given-names></name><name><surname>Ren</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Fang</surname><given-names>W</given-names></name><name><surname>Meng</surname><given-names>Q</given-names></name><name><surname>Kijlstra</surname><given-names>A</given-names></name></person-group><article-title>Clinical characteristics of Vogt-Koyanagi-Harada syndrome in Chinese patients.</article-title><source>Ophthalmology</source><year>2007</year><volume>114</volume><fpage>606</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">17123618</pub-id></citation></ref><ref id="r5"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ishikawa</surname><given-names>A</given-names></name><name><surname>Shiono</surname><given-names>T</given-names></name><name><surname>Uchida</surname><given-names>S</given-names></name></person-group><article-title>Vogt-Koyanagi-Harada disease in identical twins.</article-title><source>Retina</source><year>1994</year><volume>14</volume><fpage>435</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">7899719</pub-id></citation></ref><ref id="r6"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rutzen</surname><given-names>AR</given-names></name><name><surname>Ortega-Larrocea</surname><given-names>G</given-names></name><name><surname>Schwab</surname><given-names>IR</given-names></name><name><surname>Rao</surname><given-names>NA</given-names></name></person-group><article-title>Simultaneous onset of Vogt-Koyanagi-Harada syndrome in monozygotic twins.</article-title><source>Am J Ophthalmol</source><year>1995</year><volume>119</volume><fpage>239</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">7832237</pub-id></citation></ref><ref id="r7"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Itho</surname><given-names>S</given-names></name><name><surname>Kurimoto</surname><given-names>S</given-names></name><name><surname>Kouno</surname><given-names>T</given-names></name></person-group><article-title>Vogt-Koyanagi-Harada disease in monozygotic twins.</article-title><source>Int Ophthalmol</source><year>1992</year><volume>16</volume><fpage>49</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">1537650</pub-id></citation></ref><ref id="r8"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>M</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Abrahams</surname><given-names>IW</given-names></name></person-group><article-title>Association of HLA antigens with Vogt-Koyanagi-Harada syndrome in a Han Chinese population.</article-title><source>Arch Ophthalmol</source><year>1991</year><volume>109</volume><fpage>368</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">2003797</pub-id></citation></ref><ref id="r9"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>XY</given-names></name><name><surname>Wang</surname><given-names>XM</given-names></name><name><surname>Hu</surname><given-names>TS</given-names></name></person-group><article-title>Profiling human leukocyte antigens in Vogt-Koyanagi-Harada syndrome.</article-title><source>Am J Ophthalmol</source><year>1992</year><volume>113</volume><fpage>567</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">1575232</pub-id></citation></ref><ref id="r10"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Islam</surname><given-names>SM</given-names></name><name><surname>Numaga</surname><given-names>J</given-names></name><name><surname>Fujino</surname><given-names>Y</given-names></name><name><surname>Hirata</surname><given-names>R</given-names></name><name><surname>Matsuki</surname><given-names>K</given-names></name><name><surname>Maeda</surname><given-names>H</given-names></name><name><surname>Masuda</surname><given-names>K</given-names></name></person-group><article-title>HLA class II genes in Vogt-Koyanagi-Harada disease.</article-title><source>Invest Ophthalmol Vis Sci</source><year>1994</year><volume>35</volume><fpage>3890</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">7928186</pub-id></citation></ref><ref id="r11"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>P</given-names></name><name><surname>Hou</surname><given-names>S</given-names></name><name><surname>Lin</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Kijlstra</surname><given-names>A</given-names></name></person-group><article-title>Association of the CTLA-4 gene with Vogt-Koyanagi-Harada syndrome.</article-title><source>Clin Immunol</source><year>2008</year><volume>127</volume><fpage>43</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">18282809</pub-id></citation></ref><ref id="r12"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Horie</surname><given-names>Y</given-names></name><name><surname>Takemoto</surname><given-names>Y</given-names></name><name><surname>Miyazaki</surname><given-names>A</given-names></name><name><surname>Namba</surname><given-names>K</given-names></name><name><surname>Kase</surname><given-names>S</given-names></name><name><surname>Yoshida</surname><given-names>K</given-names></name><name><surname>Ota</surname><given-names>M</given-names></name><name><surname>Hasumi</surname><given-names>Y</given-names></name><name><surname>Inoko</surname><given-names>H</given-names></name><name><surname>Mizuki</surname><given-names>N</given-names></name><name><surname>Ohno</surname><given-names>S</given-names></name></person-group><article-title>Tyrosinase gene family and Vogt-Koyanagi-Harada disease in Japanese patients.</article-title><source>Mol Vis</source><year>2006</year><volume>12</volume><fpage>1601</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">17200659</pub-id></citation></ref><ref id="r13"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Horie</surname><given-names>Y</given-names></name><name><surname>Kitaichi</surname><given-names>N</given-names></name><name><surname>Takemoto</surname><given-names>Y</given-names></name><name><surname>Namba</surname><given-names>K</given-names></name><name><surname>Yoshida</surname><given-names>K</given-names></name><name><surname>Hirose</surname><given-names>S</given-names></name><name><surname>Hasumi</surname><given-names>Y</given-names></name><name><surname>Ota</surname><given-names>M</given-names></name><name><surname>Inoko</surname><given-names>H</given-names></name><name><surname>Mizuki</surname><given-names>N</given-names></name><name><surname>Ohno</surname><given-names>S</given-names></name></person-group><article-title>Polymorphism of IFN-gamma gene and Vogt-Koyanagi-Harada disease.</article-title><source>Mol Vis</source><year>2007</year><volume>13</volume><fpage>2334</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">18199975</pub-id></citation></ref><ref id="r14"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><collab>Wellcome Trust Case Control Consortium</collab></person-group><article-title>Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls.</article-title><source>Nature</source><year>2007</year><volume>447</volume><fpage>661</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">17554300</pub-id></citation></ref><ref id="r15"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cargill</surname><given-names>M</given-names></name><name><surname>Schrodi</surname><given-names>SJ</given-names></name><name><surname>Chang</surname><given-names>M</given-names></name><name><surname>Garcia</surname><given-names>VE</given-names></name><name><surname>Brandon</surname><given-names>R</given-names></name><name><surname>Callis</surname><given-names>KP</given-names></name><name><surname>Matsunami</surname><given-names>N</given-names></name><name><surname>Ardlie</surname><given-names>KG</given-names></name><name><surname>Civello</surname><given-names>D</given-names></name><name><surname>Catanese</surname><given-names>JJ</given-names></name><name><surname>Leong</surname><given-names>DU</given-names></name><name><surname>Panko</surname><given-names>JM</given-names></name><name><surname>McAllister</surname><given-names>LB</given-names></name><name><surname>Hansen</surname><given-names>CB</given-names></name><name><surname>Papenfuss</surname><given-names>J</given-names></name><name><surname>Prescott</surname><given-names>SM</given-names></name><name><surname>White</surname><given-names>TJ</given-names></name><name><surname>Leppert</surname><given-names>MF</given-names></name><name><surname>Krueger</surname><given-names>GG</given-names></name><name><surname>Begovich</surname><given-names>AB</given-names></name></person-group><article-title>A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes.</article-title><source>Am J Hum Genet</source><year>2007</year><volume>80</volume><fpage>273</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">17236132</pub-id></citation></ref><ref id="r16"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Burton</surname><given-names>PR</given-names></name><name><surname>Clayton</surname><given-names>DG</given-names></name><name><surname>Cardon</surname><given-names>LR</given-names></name><name><surname>Craddock</surname><given-names>N</given-names></name><name><surname>Deloukas</surname><given-names>P</given-names></name><name><surname>Duncanson</surname><given-names>A</given-names></name><name><surname>Kwiatkowski</surname><given-names>DP</given-names></name><name><surname>McCarthy</surname><given-names>MI</given-names></name><name><surname>Ouwehand</surname><given-names>WH</given-names></name><name><surname>Samani</surname><given-names>NJ</given-names></name><name><surname>Todd</surname><given-names>JA</given-names></name><name><surname>Donnelly</surname><given-names>P</given-names></name><name><surname>Barrett</surname><given-names>JC</given-names></name><name><surname>Davison</surname><given-names>D</given-names></name><name><surname>Easton</surname><given-names>D</given-names></name><name><surname>Evans</surname><given-names>DM</given-names></name><name><surname>Leung</surname><given-names>HT</given-names></name><name><surname>Marchini</surname><given-names>JL</given-names></name><name><surname>Morris</surname><given-names>AP</given-names></name><name><surname>Spencer</surname><given-names>CC</given-names></name><name><surname>Tobin</surname><given-names>MD</given-names></name><name><surname>Attwood</surname><given-names>AP</given-names></name><name><surname>Boorman</surname><given-names>JP</given-names></name><name><surname>Cant</surname><given-names>B</given-names></name><name><surname>Everson</surname><given-names>U</given-names></name><name><surname>Hussey</surname><given-names>JM</given-names></name><name><surname>Jolley</surname><given-names>JD</given-names></name><name><surname>Knight</surname><given-names>AS</given-names></name><name><surname>Koch</surname><given-names>K</given-names></name><name><surname>Meech</surname><given-names>E</given-names></name><name><surname>Nutland</surname><given-names>S</given-names></name><name><surname>Prowse</surname><given-names>CV</given-names></name><name><surname>Stevens</surname><given-names>HE</given-names></name><name><surname>Taylor</surname><given-names>NC</given-names></name><name><surname>Walters</surname><given-names>GR</given-names></name><name><surname>Walker</surname><given-names>NM</given-names></name><name><surname>Watkins</surname><given-names>NA</given-names></name><name><surname>Winzer</surname><given-names>T</given-names></name><name><surname>Jones</surname><given-names>RW</given-names></name><name><surname>McArdle</surname><given-names>WL</given-names></name><name><surname>Ring</surname><given-names>SM</given-names></name><name><surname>Strachan</surname><given-names>DP</given-names></name><name><surname>Pembrey</surname><given-names>M</given-names></name><name><surname>Breen</surname><given-names>G</given-names></name><name><surname>St Clair</surname><given-names>D</given-names></name><name><surname>Caesar</surname><given-names>S</given-names></name><name><surname>Gordon-Smith</surname><given-names>K</given-names></name><name><surname>Jones</surname><given-names>L</given-names></name><name><surname>Fraser</surname><given-names>C</given-names></name><name><surname>Green</surname><given-names>EK</given-names></name><name><surname>Grozeva</surname><given-names>D</given-names></name><name><surname>Hamshere</surname><given-names>ML</given-names></name><name><surname>Holmans</surname><given-names>PA</given-names></name><name><surname>Jones</surname><given-names>IR</given-names></name><name><surname>Kirov</surname><given-names>G</given-names></name><name><surname>Moskivina</surname><given-names>V</given-names></name><name><surname>Nikolov</surname><given-names>I</given-names></name><name><surname>O'Donovan</surname><given-names>MC</given-names></name><name><surname>Owen</surname><given-names>MJ</given-names></name><name><surname>Collier</surname><given-names>DA</given-names></name><name><surname>Elkin</surname><given-names>A</given-names></name><name><surname>Farmer</surname><given-names>A</given-names></name><name><surname>Williamson</surname><given-names>R</given-names></name><name><surname>McGuffin</surname><given-names>P</given-names></name><name><surname>Young</surname><given-names>AH</given-names></name><name><surname>Ferrier</surname><given-names>IN</given-names></name><name><surname>Ball</surname><given-names>SG</given-names></name><name><surname>Balmforth</surname><given-names>AJ</given-names></name><name><surname>Barrett</surname><given-names>JH</given-names></name><name><surname>Bishop</surname><given-names>TD</given-names></name><name><surname>Iles</surname><given-names>MM</given-names></name><name><surname>Maqbool</surname><given-names>A</given-names></name><name><surname>Yuldasheva</surname><given-names>N</given-names></name><name><surname>Hall</surname><given-names>AS</given-names></name><name><surname>Braund</surname><given-names>PS</given-names></name><name><surname>Dixon</surname><given-names>RJ</given-names></name><name><surname>Mangino</surname><given-names>M</given-names></name><name><surname>Stevens</surname><given-names>S</given-names></name><name><surname>Thompson</surname><given-names>JR</given-names></name><name><surname>Bredin</surname><given-names>F</given-names></name><name><surname>Tremelling</surname><given-names>M</given-names></name><name><surname>Parkes</surname><given-names>M</given-names></name><name><surname>Drummond</surname><given-names>H</given-names></name><name><surname>Lees</surname><given-names>CW</given-names></name><name><surname>Nimmo</surname><given-names>ER</given-names></name><name><surname>Satsangi</surname><given-names>J</given-names></name><name><surname>Fisher</surname><given-names>SA</given-names></name><name><surname>Forbes</surname><given-names>A</given-names></name><name><surname>Lewis</surname><given-names>CM</given-names></name><name><surname>Onnie</surname><given-names>CM</given-names></name><name><surname>Prescott</surname><given-names>NJ</given-names></name><name><surname>Sanderson</surname><given-names>J</given-names></name><name><surname>Matthew</surname><given-names>CG</given-names></name><name><surname>Barbour</surname><given-names>J</given-names></name><name><surname>Mohiuddin</surname><given-names>MK</given-names></name><name><surname>Todhunter</surname><given-names>CE</given-names></name><name><surname>Mansfield</surname><given-names>JC</given-names></name><name><surname>Ahmad</surname><given-names>T</given-names></name><name><surname>Cummings</surname><given-names>FR</given-names></name><name><surname>Jewell</surname><given-names>DP</given-names></name><name><surname>Webster</surname><given-names>J</given-names></name><name><surname>Brown</surname><given-names>MJ</given-names></name><name><surname>Lathrop</surname><given-names>MG</given-names></name><name><surname>Connell</surname><given-names>J</given-names></name><name><surname>Dominiczak</surname><given-names>A</given-names></name><name><surname>Marcano</surname><given-names>CA</given-names></name><name><surname>Burke</surname><given-names>B</given-names></name><name><surname>Dobson</surname><given-names>R</given-names></name><name><surname>Gungadoo</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>KL</given-names></name><name><surname>Munroe</surname><given-names>PB</given-names></name><name><surname>Newhouse</surname><given-names>SJ</given-names></name><name><surname>Onipinla</surname><given-names>A</given-names></name><name><surname>Wallace</surname><given-names>C</given-names></name><name><surname>Xue</surname><given-names>M</given-names></name><name><surname>Caulfield</surname><given-names>M</given-names></name><name><surname>Farrall</surname><given-names>M</given-names></name><name><surname>Barton</surname><given-names>A</given-names></name><name><surname>Bruce</surname><given-names>IN</given-names></name><name><surname>Donovan</surname><given-names>H</given-names></name><name><surname>Eyre</surname><given-names>S</given-names></name><name><surname>Gilbert</surname><given-names>PD</given-names></name><name><surname>Hilder</surname><given-names>SL</given-names></name><name><surname>Hinks</surname><given-names>AM</given-names></name><name><surname>John</surname><given-names>SL</given-names></name><name><surname>Potter</surname><given-names>C</given-names></name><name><surname>Silman</surname><given-names>AJ</given-names></name><name><surname>Symmons</surname><given-names>DP</given-names></name><name><surname>Thomson</surname><given-names>W</given-names></name><name><surname>Worthington</surname><given-names>J</given-names></name><name><surname>Dunger</surname><given-names>DB</given-names></name><name><surname>Widmer</surname><given-names>B</given-names></name><name><surname>Frayling</surname><given-names>TM</given-names></name><name><surname>Freathy</surname><given-names>RM</given-names></name><name><surname>Lango</surname><given-names>H</given-names></name><name><surname>Perry</surname><given-names>JR</given-names></name><name><surname>Shields</surname><given-names>BM</given-names></name><name><surname>Weedon</surname><given-names>MN</given-names></name><name><surname>Hattersley</surname><given-names>AT</given-names></name><name><surname>Hitman</surname><given-names>GA</given-names></name><name><surname>Walker</surname><given-names>M</given-names></name><name><surname>Elliott</surname><given-names>KS</given-names></name><name><surname>Groves</surname><given-names>CJ</given-names></name><name><surname>Lindgren</surname><given-names>CM</given-names></name><name><surname>Rayner</surname><given-names>NW</given-names></name><name><surname>Timpson</surname><given-names>NJ</given-names></name><name><surname>Zeggini</surname><given-names>E</given-names></name><name><surname>Newport</surname><given-names>M</given-names></name><name><surname>Sirugo</surname><given-names>G</given-names></name><name><surname>Lyons</surname><given-names>E</given-names></name><name><surname>Vannberg</surname><given-names>F</given-names></name><name><surname>Hill</surname><given-names>AV</given-names></name><name><surname>Bradbury</surname><given-names>LA</given-names></name><name><surname>Farrar</surname><given-names>C</given-names></name><name><surname>Pointon</surname><given-names>JJ</given-names></name><name><surname>Wordsworth</surname><given-names>P</given-names></name><name><surname>Brown</surname><given-names>MA</given-names></name><name><surname>Franklyn</surname><given-names>JA</given-names></name><name><surname>Heward</surname><given-names>JM</given-names></name><name><surname>Simmonds</surname><given-names>MJ</given-names></name><name><surname>Gough</surname><given-names>SC</given-names></name><name><surname>Seal</surname><given-names>S</given-names></name><name><surname>Stratton</surname><given-names>MR</given-names></name><name><surname>Rahman</surname><given-names>N</given-names></name><name><surname>Ban</surname><given-names>M</given-names></name><name><surname>Goris</surname><given-names>A</given-names></name><name><surname>Sawcer</surname><given-names>SJ</given-names></name><name><surname>Compston</surname><given-names>A</given-names></name><name><surname>Conway</surname><given-names>D</given-names></name><name><surname>Jallow</surname><given-names>M</given-names></name><name><surname>Newport</surname><given-names>M</given-names></name><name><surname>Sirugo</surname><given-names>G</given-names></name><name><surname>Rockett</surname><given-names>KA</given-names></name><name><surname>Bumpstead</surname><given-names>SJ</given-names></name><name><surname>Chaney</surname><given-names>A</given-names></name><name><surname>Downes</surname><given-names>K</given-names></name><name><surname>Ghori</surname><given-names>MJ</given-names></name><name><surname>Gwilliam</surname><given-names>R</given-names></name><name><surname>Hunt</surname><given-names>SE</given-names></name><name><surname>Inouye</surname><given-names>M</given-names></name><name><surname>Keniry</surname><given-names>A</given-names></name><name><surname>King</surname><given-names>E</given-names></name><name><surname>McGinnis</surname><given-names>R</given-names></name><name><surname>Potter</surname><given-names>S</given-names></name><name><surname>Ravindrarajah</surname><given-names>R</given-names></name><name><surname>Whittaker</surname><given-names>P</given-names></name><name><surname>Widden</surname><given-names>C</given-names></name><name><surname>Withers</surname><given-names>D</given-names></name><name><surname>Cardin</surname><given-names>NJ</given-names></name><name><surname>Davison</surname><given-names>D</given-names></name><name><surname>Ferreira</surname><given-names>T</given-names></name><name><surname>Pereira-Gale</surname><given-names>J</given-names></name><name><surname>Hallgrimsdo'ttir</surname><given-names>IB</given-names></name><name><surname>Howie</surname><given-names>BN</given-names></name><name><surname>Su</surname><given-names>Z</given-names></name><name><surname>Teo</surname><given-names>YY</given-names></name><name><surname>Vukcevic</surname><given-names>D</given-names></name><name><surname>Bentley</surname><given-names>D</given-names></name><name><surname>Brown</surname><given-names>MA</given-names></name><name><surname>Compston</surname><given-names>A</given-names></name><name><surname>Farrall</surname><given-names>M</given-names></name><name><surname>Hall</surname><given-names>AS</given-names></name><name><surname>Hattersley</surname><given-names>AT</given-names></name><name><surname>Hill</surname><given-names>AV</given-names></name><name><surname>Parkes</surname><given-names>M</given-names></name><name><surname>Pembrey</surname><given-names>M</given-names></name><name><surname>Stratton</surname><given-names>MR</given-names></name><name><surname>Mitchell</surname><given-names>SL</given-names></name><name><surname>Newby</surname><given-names>PR</given-names></name><name><surname>Brand</surname><given-names>OJ</given-names></name><name><surname>Carr-Smith</surname><given-names>J</given-names></name><name><surname>Pearce</surname><given-names>SH</given-names></name><name><surname>McGinnis</surname><given-names>R</given-names></name><name><surname>Keniry</surname><given-names>A</given-names></name><name><surname>Deloukas</surname><given-names>P</given-names></name><name><surname>Reveille</surname><given-names>JD</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Sims</surname><given-names>AM</given-names></name><name><surname>Dowling</surname><given-names>A</given-names></name><name><surname>Taylor</surname><given-names>J</given-names></name><name><surname>Doan</surname><given-names>T</given-names></name><name><surname>Davis</surname><given-names>JC</given-names></name><name><surname>Savage</surname><given-names>L</given-names></name><name><surname>Ward</surname><given-names>MM</given-names></name><name><surname>Learch</surname><given-names>TL</given-names></name><name><surname>Weisman</surname><given-names>MH</given-names></name><name><surname>Brown</surname><given-names>M</given-names></name></person-group><article-title>Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants.</article-title><source>Nat Genet</source><year>2007</year><volume>39</volume><fpage>1329</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">17952073</pub-id></citation></ref><ref id="r17"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Duerr</surname><given-names>RH</given-names></name><name><surname>Taylor</surname><given-names>KD</given-names></name><name><surname>Brant</surname><given-names>SR</given-names></name><name><surname>Rioux</surname><given-names>JD</given-names></name><name><surname>Silverberg</surname><given-names>MS</given-names></name><name><surname>Daly</surname><given-names>MJ</given-names></name><name><surname>Steinhart</surname><given-names>AH</given-names></name><name><surname>Abraham</surname><given-names>C</given-names></name><name><surname>Regueiro</surname><given-names>M</given-names></name><name><surname>Griffiths</surname><given-names>A</given-names></name><name><surname>Dassopoulos</surname><given-names>T</given-names></name><name><surname>Bitton</surname><given-names>A</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Targan</surname><given-names>S</given-names></name><name><surname>Datta</surname><given-names>LW</given-names></name><name><surname>Kistner</surname><given-names>EO</given-names></name><name><surname>Schumm</surname><given-names>LP</given-names></name><name><surname>Lee</surname><given-names>AT</given-names></name><name><surname>Gregersen</surname><given-names>PK</given-names></name><name><surname>Barmada</surname><given-names>MM</given-names></name><name><surname>Rotter</surname><given-names>JI</given-names></name><name><surname>Nicolae</surname><given-names>DL</given-names></name><name><surname>Cho</surname><given-names>JH</given-names></name></person-group><article-title>A genome-wide association study identifies IL23R as an inflammatory bowel disease gene.</article-title><source>Science</source><year>2006</year><volume>314</volume><fpage>1461</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">17068223</pub-id></citation></ref><ref id="r18"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>P</given-names></name><name><surname>Eckenrode</surname><given-names>S</given-names></name><name><surname>Hopkins</surname><given-names>D</given-names></name><name><surname>Zheng</surname><given-names>W</given-names></name><name><surname>Purohit</surname><given-names>S</given-names></name><name><surname>Podolsky</surname><given-names>RH</given-names></name><name><surname>Muir</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Dong</surname><given-names>Z</given-names></name><name><surname>Brusko</surname><given-names>T</given-names></name><name><surname>Atkinson</surname><given-names>M</given-names></name><name><surname>Pozzilli</surname><given-names>P</given-names></name><name><surname>Zeidler</surname><given-names>A</given-names></name><name><surname>Raffel</surname><given-names>LJ</given-names></name><name><surname>Jacob</surname><given-names>CO</given-names></name><name><surname>Park</surname><given-names>Y</given-names></name><name><surname>Serrano-Rios</surname><given-names>M</given-names></name><name><surname>Larrad</surname><given-names>MT</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Garchon</surname><given-names>HJ</given-names></name><name><surname>Bach</surname><given-names>JF</given-names></name><name><surname>Rotter</surname><given-names>JI</given-names></name><name><surname>She</surname><given-names>JX</given-names></name><name><surname>Wang</surname><given-names>CY</given-names></name></person-group><article-title>A functional variant of SUMO4, a new I kappa B alpha modifier, is associated with type 1 diabetes.</article-title><source>Nat Genet</source><year>2004</year><volume>36</volume><fpage>837</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">15247916</pub-id></citation></ref><ref id="r19"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tsurumaru</surname><given-names>M</given-names></name><name><surname>Kawasaki</surname><given-names>E</given-names></name><name><surname>Ida</surname><given-names>H</given-names></name><name><surname>Migita</surname><given-names>K</given-names></name><name><surname>Moriuchi</surname><given-names>A</given-names></name><name><surname>Fukushima</surname><given-names>K</given-names></name><name><surname>Fukushima</surname><given-names>T</given-names></name><name><surname>Abiru</surname><given-names>N</given-names></name><name><surname>Yamasaki</surname><given-names>H</given-names></name><name><surname>Noso</surname><given-names>S</given-names></name><name><surname>Ikegami</surname><given-names>H</given-names></name><name><surname>Awata</surname><given-names>T</given-names></name><name><surname>Sasaki</surname><given-names>H</given-names></name><name><surname>Eguchi</surname><given-names>K</given-names></name></person-group><article-title>Evidence for the role of small ubiquitin-like modifier 4 as a general autoimmunity locus in the Japanese population.</article-title><source>J Clin Endocrinol Metab</source><year>2006</year><volume>91</volume><fpage>3138</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">16735488</pub-id></citation></ref><ref id="r20"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Noso</surname><given-names>S</given-names></name><name><surname>Fujisawa</surname><given-names>T</given-names></name><name><surname>Kawabata</surname><given-names>Y</given-names></name><name><surname>Asano</surname><given-names>K</given-names></name><name><surname>Hiromine</surname><given-names>Y</given-names></name><name><surname>Fukai</surname><given-names>A</given-names></name><name><surname>Ogihara</surname><given-names>T</given-names></name><name><surname>Ikegami</surname><given-names>H</given-names></name></person-group><article-title>Association of small ubiquitin-like modifier 4 (SUMO4) variant, located in IDDM5 locus, with type 2 diabetes in the Japanese population.</article-title><source>J Clin Endocrinol Metab</source><year>2007</year><volume>92</volume><fpage>2358</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">17374705</pub-id></citation></ref><ref id="r21"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>HY</given-names></name><name><surname>Wang</surname><given-names>CL</given-names></name><name><surname>Hsiao</surname><given-names>PJ</given-names></name><name><surname>Lu</surname><given-names>YC</given-names></name><name><surname>Chen</surname><given-names>SY</given-names></name><name><surname>Lin</surname><given-names>KD</given-names></name><name><surname>Hsin</surname><given-names>SC</given-names></name><name><surname>Hsieh</surname><given-names>MC</given-names></name><name><surname>Shin</surname><given-names>SJ</given-names></name></person-group><article-title>SUMO4 M55V variant is associated with diabetic nephropathy in type 2 diabetes.</article-title><source>Diabetes</source><year>2007</year><volume>56</volume><fpage>1177</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">17229939</pub-id></citation></ref><ref id="r22"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hou</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>P</given-names></name><name><surname>Du</surname><given-names>L</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Lin</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Kijlstra</surname><given-names>A</given-names></name></person-group><article-title>SUMO4 gene polymorphisms in Chinese Han patients with Behcet's disease.</article-title><source>Clin Immunol</source><year>2008</year><volume>129</volume><fpage>170</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">18657476</pub-id></citation></ref><ref id="r23"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Owerbach</surname><given-names>D</given-names></name><name><surname>Pina</surname><given-names>L</given-names></name><name><surname>Gabbay</surname><given-names>KH</given-names></name></person-group><article-title>A 212-kb region on chromosome 6q25 containing the TAB2 gene is associated with susceptibility to type 1 diabetes.</article-title><source>Diabetes</source><year>2004</year><volume>53</volume><fpage>1890</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">15220215</pub-id></citation></ref><ref id="r24"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Qu</surname><given-names>H</given-names></name><name><surname>Bharaj</surname><given-names>B</given-names></name><name><surname>Liu</surname><given-names>XQ</given-names></name><name><surname>Curtis</surname><given-names>JA</given-names></name><name><surname>Newhook</surname><given-names>LA</given-names></name><name><surname>Paterson</surname><given-names>AD</given-names></name><name><surname>Hudson</surname><given-names>TJ</given-names></name><name><surname>Polychronakos</surname><given-names>C</given-names></name></person-group><article-title>Assessing the validity of the association between the SUMO4 M55V variant and risk of type 1 diabetes.</article-title><source>Nat Genet</source><year>2005</year><volume>37</volume><fpage>111</fpage><lpage>2</lpage><comment>author reply 2&#x02013;3</comment><pub-id pub-id-type="pmid">15678135</pub-id></citation></ref><ref id="r25"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Smyth</surname><given-names>DJ</given-names></name><name><surname>Howson</surname><given-names>JM</given-names></name><name><surname>Lowe</surname><given-names>CE</given-names></name><name><surname>Walker</surname><given-names>NM</given-names></name><name><surname>Lam</surname><given-names>AC</given-names></name><name><surname>Nutland</surname><given-names>S</given-names></name><name><surname>Hutchings</surname><given-names>J</given-names></name><name><surname>Tuomilehto-Wolf</surname><given-names>E</given-names></name><name><surname>Tuomilehto</surname><given-names>J</given-names></name><name><surname>Guja</surname><given-names>C</given-names></name><name><surname>Ionescu-Tirgoviste</surname><given-names>C</given-names></name><name><surname>Undlien</surname><given-names>DE</given-names></name><name><surname>Ronningen</surname><given-names>KS</given-names></name><name><surname>Savage</surname><given-names>D</given-names></name><name><surname>Dunger</surname><given-names>DB</given-names></name><name><surname>Twells</surname><given-names>RC</given-names></name><name><surname>McArdle</surname><given-names>WL</given-names></name><name><surname>Strachan</surname><given-names>DP</given-names></name><name><surname>Todd</surname><given-names>JA</given-names></name></person-group><article-title>Assessing the validity of the association between the SUMO4 M55V variant and risk of type 1 diabetes.</article-title><source>Nat Genet</source><year>2005</year><volume>37</volume><fpage>110</fpage><lpage>1</lpage><comment>author reply 2&#x02013;3</comment><pub-id pub-id-type="pmid">15678134</pub-id></citation></ref><ref id="r26"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zetterquist</surname><given-names>H</given-names></name><name><surname>Olerup</surname><given-names>O</given-names></name></person-group><article-title>Identification of the HLA-DRB1*04, -DRB1*07, and -DRB1*09 alleles by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours.</article-title><source>Hum Immunol</source><year>1992</year><volume>34</volume><fpage>64</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">1356957</pub-id></citation></ref><ref id="r27"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Richeldi</surname><given-names>L</given-names></name><name><surname>Sorrentino</surname><given-names>R</given-names></name><name><surname>Saltini</surname><given-names>C</given-names></name></person-group><article-title>HLA-DPB1 glutamate 69: a genetic marker of beryllium disease.</article-title><source>Science</source><year>1993</year><volume>262</volume><fpage>242</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">8105536</pub-id></citation></ref><ref id="r28"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barrett</surname><given-names>JC</given-names></name><name><surname>Fry</surname><given-names>B</given-names></name><name><surname>Maller</surname><given-names>J</given-names></name><name><surname>Daly</surname><given-names>MJ</given-names></name></person-group><article-title>Haploview: analysis and visualization of LD and haplotype maps.</article-title><source>Bioinformatics</source><year>2005</year><volume>21</volume><fpage>263</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">15297300</pub-id></citation></ref><ref id="r29"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Qin</surname><given-names>ZS</given-names></name><name><surname>Niu</surname><given-names>T</given-names></name><name><surname>Liu</surname><given-names>JS</given-names></name></person-group><article-title>Partition-ligation-expectation-maximization algorithm for haplotype inference with single-nucleotide polymorphisms.</article-title><source>Am J Hum Genet</source><year>2002</year><volume>71</volume><fpage>1242</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">12452179</pub-id></citation></ref><ref id="r30"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Read</surname><given-names>RW</given-names></name><name><surname>Holland</surname><given-names>GN</given-names></name><name><surname>Rao</surname><given-names>NA</given-names></name><name><surname>Tabbara</surname><given-names>KF</given-names></name><name><surname>Ohno</surname><given-names>S</given-names></name><name><surname>Arellanes-Garcia</surname><given-names>L</given-names></name><name><surname>Pivetti-Pezzi</surname><given-names>P</given-names></name><name><surname>Tessler</surname><given-names>HH</given-names></name><name><surname>Usui</surname><given-names>M</given-names></name></person-group><article-title>Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature.</article-title><source>Am J Ophthalmol</source><year>2001</year><volume>131</volume><fpage>647</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">11336942</pub-id></citation></ref><ref id="r31"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Gao</surname><given-names>L</given-names></name><name><surname>Shen</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>CY</given-names></name><name><surname>Li</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Lv</surname><given-names>YJ</given-names></name><name><surname>Li</surname><given-names>CX</given-names></name><name><surname>Gao</surname><given-names>TW</given-names></name><name><surname>Liu</surname><given-names>YF</given-names></name></person-group><article-title>Association study of NFKB1 and SUMO4 polymorphisms in Chinese patients with psoriasis vulgaris.</article-title><source>Arch Dermatol Res</source><year>2008</year><volume>300</volume><fpage>425</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">18330586</pub-id></citation></ref><ref id="r32"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Noso</surname><given-names>S</given-names></name><name><surname>Ikegami</surname><given-names>H</given-names></name><name><surname>Fujisawa</surname><given-names>T</given-names></name><name><surname>Kawabata</surname><given-names>Y</given-names></name><name><surname>Asano</surname><given-names>K</given-names></name><name><surname>Hiromine</surname><given-names>Y</given-names></name><name><surname>Tsurumaru</surname><given-names>M</given-names></name><name><surname>Sugihara</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>I</given-names></name><name><surname>Kawasaki</surname><given-names>E</given-names></name><name><surname>Awata</surname><given-names>T</given-names></name><name><surname>Ogihara</surname><given-names>T</given-names></name></person-group><article-title>Genetic heterogeneity in association of the SUMO4 M55V variant with susceptibility to type 1 diabetes.</article-title><source>Diabetes</source><year>2005</year><volume>54</volume><fpage>3582</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">16306380</pub-id></citation></ref><ref id="r33"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Inomata</surname><given-names>H</given-names></name><name><surname>Minei</surname><given-names>M</given-names></name><name><surname>Taniguchi</surname><given-names>Y</given-names></name><name><surname>Nishimura</surname><given-names>F</given-names></name></person-group><article-title>Choroidal neovascularization in long-standing case of Vogt-Koyanagi-Harada disease.</article-title><source>Jpn J Ophthalmol</source><year>1983</year><volume>27</volume><fpage>9</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">6190031</pub-id></citation></ref><ref id="r34"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>T</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>You</surname><given-names>X</given-names></name></person-group><article-title>The association of HLA-DR4 gene subtypes with Vogt-Koyanagi-Harada syndrome.</article-title><source>Zhonghua Yan Ke Za Zhi</source><year>1997</year><volume>33</volume><fpage>268</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">10451958</pub-id></citation></ref><ref id="r35"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weisz</surname><given-names>JM</given-names></name><name><surname>Holland</surname><given-names>GN</given-names></name><name><surname>Roer</surname><given-names>LN</given-names></name><name><surname>Park</surname><given-names>MS</given-names></name><name><surname>Yuge</surname><given-names>AJ</given-names></name><name><surname>Moorthy</surname><given-names>RS</given-names></name><name><surname>Forster</surname><given-names>DJ</given-names></name><name><surname>Rao</surname><given-names>NA</given-names></name><name><surname>Terasaki</surname><given-names>PI</given-names></name></person-group><article-title>Association between Vogt-Koyanagi-Harada syndrome and HLA-DR1 and -DR4 in Hispanic patients living in southern California.</article-title><source>Ophthalmology</source><year>1995</year><volume>102</volume><fpage>1012</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">9121744</pub-id></citation></ref></ref-list></back></article> 